Alder BioPharmaceuticals, Inc. (ALDR)
(Delayed Data from NSDQ)
$12.28 USD
+0.04 (0.33%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.28 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.28 USD
+0.04 (0.33%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.28 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Strong Buy
by Zacks Equity Research
Alder BioPharmaceuticals (ALDR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap
by Zacks Equity Research
Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap
Use Rising P/E Strategy to Grab 5 Winning Stocks
by Sanghamitra Saha
Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.
Company News For Sep 17, 2019
by Zacks Equity Research
Companies in the news are: ALDR, GM, NEWR, SEMG
Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck
by Zacks Equity Research
Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.
Alder BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Alder BioPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
MyoKardia Begins Dosing in Phase I Study on Heart Candidate
by Zacks Equity Research
MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.
NuCana Stops Patient Enrollment in Pancreatic Cancer Study
by Zacks Equity Research
NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.
What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?
by Zacks Equity Research
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.
Alder Biopharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Alder Biopharmaceuticals, Inc. (ALDR) has been struggling lately, but the selling pressure may be coming to an end soon.
All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Buy
by Zacks Equity Research
Alder BioPharmaceuticals (ALDR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
by Zacks Equity Research
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
Molina Healthcare (MOH) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter earnings trump estimates on the back of lower costs and higher premium revenues.
Ensign Group's (ENSG) Q4 Earnings Top Estimates, Surge Y/Y
by Zacks Equity Research
Ensign Group's (ENSG) fourth-quarter earnings rise on the back of solid segmental growth.
MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y
by Zacks Equity Research
Mednax's (MD) Q4 gains on revenue growth. However, the same is partly offset by rise in expenses.
Is a Beat in Store for Molina Healthcare (MOH) Q4 Earnings?
by Zacks Equity Research
Molina Healthcare (MOH) is expected to gain in Q4 on the back of membership strength and its streamlining initiative. However, the same might be partly offset by a dismal Marketplace business.
Alder BioPharmaceuticals (ALDR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Alder BioPharmaceuticals (ALDR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
by Zacks Equity Research
MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.
Will Alder BioPharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Alder BioPharmaceuticals.
The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
4 Healthcare Stocks Thriving on Venture Capital Funding
by Nitish Marwah
A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.
Alder BioPharmaceuticals Enters Oversold Territory
by Zacks Equity Research
Alder BioPharmaceuticals has been on a bit of a cold streak lately.
Is Alder BioPharmaceuticals (ALDR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALDR) Outperforming Other Medical Stocks This Year?
Alder BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Alder BioPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.